What AngioDynamics (NASDAQ:ANGO) does is not easy. This small med-tech company competes with huge players like Bard (NYSE:BCR) and Covidien (NYSE:COV) (as well as Teleflex (NYSE:TFX))
in markets that are not growing all that fast and where a large
sales/marketing effort and the ability to bundle can make a significant
difference in closing sales. AngioDynamics hasn't always helped their
own cause either, with issues in manufacturing, quality control
(including a recent FDA Warning Letter), and financial reporting.
The
company is making progress, though, and seems to be nearing a point
where margins and profits could grow disproportionately to incremental
revenue growth. The company has also managed to add several products to
its portfolio that offer real benefits to health care professionals (and
savings to the facilities) and their patients. I'm not so crazy about
the valuation here, but if management could push revenue growth above 5%
the shares could still do rather well.
Follow this link for more:
AngioDynamics Still Looking For Inflection
No comments:
Post a Comment